Skip to main content
. 2011 Mar 7;3(1):1141–1157. doi: 10.3390/cancers3011141

Table 1.

Differentiation of human tumorigenic cell lines by reverse transcriptase (RT) inhibitors.

Cell line Tumor derivation Differentiation markers Reference
NB40, HL60 acute promyelocytic leukemia CD15 myeoloid marker, NBT assay a [43]
HL60 acute myelocytic leukemia CD15 myeoloid marker, NBT assay a [43]
A-375 melanoma E-cadherin [45]
PC3 prostate carcinoma PS-A, androgen receptor [45]
ARO, FRO thyroid anaplastic carcinoma thyroglobulin, thyroglobulin receptor [46]
a

Nitroblue tetrazolium (NBT) dye reduction assay.